Zydus is only the second Indian pharmaceutical company to receive DCGI’s nod for human trials with its vaccine candidate.
Pharmaceutical company Zydus Cadila said Wednesday that it had started human clinical trials with its COVID-19 vaccine candidate ZyCoV-D.
In the phase of the studies, the company will enroll over 1,000 volunteers at several clinical trial locations in India, according to an application for approval.
Phase I / II adaptive human clinical studies with ZyCoV-D started with the first human dose. The multicenter adaptive phase I / II dose increase study will evaluate the safety, tolerability and immunogenicity of the vaccine.
Earlier this month, Zydus received approval from the national authorities to start human trials for its COVID-1
It received approval a few days after India’s first native COVID-19 vaccine candidate, COVAXIN, developed by Bharat Biotech in collaboration with the Indian Medical Research Council and the National Institute of Virology, was awarded the clinical trial award by Drug Controller General on People had received from India.
Cadila Healthcare, the Group’s listed company, was traded on BSE at a price of 356.50 rupees per share, an increase of 0.81 percent over the previous closing.